Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vulvar dystrophy: a clinical follow-up.

N Mahmud1, T Murakami, Y Gyotoku

  • 1Department of Obstetrics and Gynecology, Nagasaki University School of Medicine, Japan.

Asia-Oceania Journal of Obstetrics and Gynaecology
|September 1, 1992
PubMed
Summary

Vulvar dystrophy treatment using steroid hormones effectively relieved symptoms and improved histological outcomes. No vulvar carcinoma developed in patients during the study, supporting hormone therapy for this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of menopausal symptoms on presenteeism in Japanese women.

Occupational medicine (Oxford, England)·2023
Same author

Acute filarial fever.

QJM : monthly journal of the Association of Physicians·2020
Same author

Two definitions of presenteeism: sickness presenteeism and impaired work function.

Occupational medicine (Oxford, England)·2020
Same author

Near misses and presenteeism among paramedics.

Occupational medicine (Oxford, England)·2019
Same author

Willingness to care for blood-borne virus-infected patients in Thailand.

Occupational medicine (Oxford, England)·2018
Same author

Secondary polycythaemia in a Malay girl with homozygous Hb Tak.

The Malaysian journal of pathology·2017

Area of Science:

  • Gynecology
  • Dermatology
  • Oncology

Background:

  • Vulvar dystrophy presents diagnostic challenges, particularly regarding malignant potential.
  • Systematic studies on vulvar dystrophy in Japan are scarce.
  • Vulvar dystrophy with dysplasia is considered a pre-malignant condition.

Purpose of the Study:

  • To prospectively evaluate the efficacy of conservative treatment for vulvar dystrophy.
  • To assess the impact of treatment on symptoms, morphology, and dysplasia.
  • To determine the long-term malignant potential of treated vulvar dystrophy.

Main Methods:

  • Prospective follow-up of vulvar dystrophy patients for 5 months to 4 years.
  • Initial histological diagnosis including squamous hyperplasia (with/without dysplasia) and lichen sclerosus.

Related Experiment Videos

  • Treatment protocol involving testosterone and corticosteroid therapies.
  • Re-biopsy for histological assessment post-treatment.

    • Main Results:

    • Itching was the most frequent complaint (69%).
    • Significant symptomatic relief was achieved with testosterone (lichen sclerosus) and corticosteroids (squamous hyperplasia).
    • Over 96% of patients showed >50% decrease in lesion size.
    • Re-biopsy demonstrated improvement in dysplasia, with complete resolution in mild cases.
    • No cases of vulvar carcinoma developed during the study period.

    Conclusions:

    • Steroid hormone therapy is a logical and effective treatment for vulvar dystrophy.
    • Conservative management can improve symptoms and histological findings.
    • Vulvar dystrophy, when treated, does not appear to progress to vulvar carcinoma in this cohort.